By Mark Waghorn via SWNS
A cheap antibiotic used to treat respiratory infections could treat COVID-19, according to new research from France.
In experiments, clofoctol reduced virus replication and lung symptoms in mice.
The drug could help combat the pandemic after human trials.
Lead author Dr. Jean Dubuisson, of Pasteur Institute, Lille, said: "Its antiviral and anti-inflammatory properties, associated with its safety profile and unique pharmacokinetics, make a strong case for proposing clofoctol as an affordable therapeutic candidate for the treatment of COVID-19 patients."
Vaccines have transformed the pandemic. But there is still a huge need for drugs that can treat the virus.
Immunity can wane, and access is still a major problem around the world. Also, new variants emphasize the possible need for a backup.
Repurposed drugs may have a speedier path to clinical use because they have already been shown to be safe in people.
The study in PLOS Pathogens suggests clofoctol may become an effective therapy.
COVID-19 jabs reduce hospitalizations and death, but they do not control virus transmission. Affordable medications are desperately needed.
The team accessed data from the Apteeus library, a collection of 1,942 approved drugs to identify molecules that exhibit antiviral activity against SARS-CoV-2, the virus that causes COVID-19.
They selected clofoctol based on its antiviral potency and tested their idea on infected mice.
Lab rodents given clofoctol had a decreased viral load, reduced inflammatory gene expression and less lung disease.
Dr. Dubuisson said: "Antivirals targeting SARS-CoV-2 are sorely needed.
"In this study, we screened a library of drug compounds and identified clofoctol as an antiviral against SARS-CoV-2.
"We further demonstrated that, in vivo, this compound reduces inflammatory gene expression and lowers pulmonary pathology and decreases viral load."
Future studies are needed to further understand the drug's therapeutic potential in patients because of the physiological differences with mice.
Additionally, the animals were sacrificed only two days after treatment, so longer-term effects remain unknown.
Dr. Dubuisson added: "Finally, the relatively low cost of this drug suggests that it is a potential clinical option for treatment of COVID-19 patients in resource-poor settings."
Stories and infographics by ‘Talker Research’ are available to download & ready to use. Stories and videos by ‘Talker News’ are managed by SWNS. To license content for editorial or commercial use and to see the full scope of SWNS content, please email firstname.lastname@example.org or submit an inquiry via our contact form.
What Albert Einstein, Pablo Picasso and Steve Jobs all had in common
It is estimated one-in-five people have the condition.
Dad bod dude beats the heat by swimming in a public fountain
The man, sporting a "dad-bod", can be seen doing breaststroke through the shallow waters as the person filming asks: "What...
Scientists invent robot fish that swims around hoovering up microplastics
It measures just half an inch from nose to tail.
Study: Baby blues can affect both parents at the same time
Symptoms include excessive anxiety, not being able to stop crying and feelings of hopelessness.
Why fake meat is less nutritious than the real thing
Experiments found human cells take in fewer proteins from the vegan versions - because they are harder to absorb.
Lifestyle3 days ago
Private island with a 17th Century villa on market for $2.2 million
Travel2 days ago
Man completes first-ever commute in an $83k space-age flying car
Sports2 days ago
6-year-old golf prodigy hopes to follow in the footsteps of his PGA-pro dad
Good News3 days ago
Mom cries tears of joy after hearing her autistic son speak for first time
Animals1 day ago
Florida men catch python believed to be the biggest in the state’s history
Food & Drink3 days ago
Bar charging $98.37 for one pint of beer
Video4 days ago
Watch: Retired pilot pulls Top Gun-style stunts
Funny4 days ago
9-year-old goes viral after passing out on theme park ride